Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2007 08:30 ET | Source: Eurand N.V.

Eurand to Present At Lazard Capital Markets 4th Annual Healthcare Conference

AMSTERDAM, The Netherlands, Nov. 20, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based...
November 09, 2007 08:04 ET | Source: Eurand N.V.

Eurand Reports Third Quarter 2007 Key Achievements and Financial Results

Highlights: ---------- - Cephalon, Inc. announced in August 2007 it had signed an agreement to acquire Amrix(r) (cyclobenzaprine HCl), a product developed by Eurand, from ECR...
October 17, 2007 08:48 ET | Source: Eurand N.V.

Eurand Announces Third Quarter 2007 Financial Results Conference Call

MILAN, Italy, Oct. 17, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX) will host a conference call on Friday, November 9, 2007 at 8:00 AM Eastern Daylight Time, 2:00 PM Central European Time...
September 27, 2007 08:45 ET | Source: Eurand N.V.

Eurand to Host Official Ceremony for Facility Expansion

DAYTON, Ohio, Sept. 27, 2007 (PRIME NEWSWIRE) -- Eurand, N.V. (Nasdaq:EURX) announced today that Eurand, Inc. will host a formal ceremony to mark the groundbreaking of its facility expansion in...
September 18, 2007 08:30 ET | Source: Eurand N.V.

Eurand to Present At the UBS Global Life Sciences Conference

MILAN, Italy and DAYTON, Ohio, Sept. 18, 2007 (PRIME NEWSWIRE) -- Eurand (Nasdaq:EURX) announced today that it will present at the upcoming UBS Global Life Sciences Conference at the Grand Hyatt Hotel...
September 13, 2007 09:38 ET | Source: Eurand N.V.

Eurand Appoints Two New Members to Its Board of Directors

AMSTERDAM, Sept. 13, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX) announced today the appointment of Angelo C. Malahias and Rolf A. Classon to the Eurand Board of Directors. Mr. Malahias and...
August 03, 2007 08:00 ET | Source: Eurand N.V.

Eurand Reports First Half 2007 Key Achievements and Financial Results

Highlights: -- Announced clinically and statistically significant results from two Phase III studies of lead product candidate, Zentase(tm), in April 2007 -- Granted fast track...